Tacrolimus

Generic Name
Tacrolimus
Brand Names
Advagraf, Astagraf, Envarsus, Modigraf, Prograf, Protopic, Tacforius
Drug Type
Small Molecule
Chemical Formula
C44H69NO12
CAS Number
104987-11-3
Unique Ingredient Identifier
Y5L2157C4J
Background

Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condi...

Indication

Immediate-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. Extended-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric ...

Associated Conditions
Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Oral Lichen Planus, Psoriasis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Atopic Dermatitis, Vitiligo, Moderate Atopic dermatitis
Associated Therapies
-
Clinical Trials
Related News

A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension-

First Posted Date
2005-09-19
Last Posted Date
2006-09-20
Lead Sponsor
Astellas Pharma Inc
Registration Number
NCT00189748

A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients

First Posted Date
2005-09-19
Last Posted Date
2006-09-20
Lead Sponsor
Astellas Pharma Inc
Registration Number
NCT00189761

A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients

First Posted Date
2005-09-19
Last Posted Date
2023-12-11
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Target Recruit Count
47
Registration Number
NCT00195429

Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma

Phase 2
Completed
Conditions
Asthma, Bronchial
Bronchial Asthma
First Posted Date
2005-09-19
Last Posted Date
2008-04-17
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
160
Registration Number
NCT00189722

Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma

Phase 2
Completed
Conditions
Asthma, Bronchial
Bronchial Asthma
First Posted Date
2005-09-19
Last Posted Date
2008-04-17
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
370
Registration Number
NCT00189787

A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Kidney Transplantation

Phase 3
Completed
Conditions
Kidney Transplantation
Interventions
Drug: tacrolimus
First Posted Date
2005-09-19
Last Posted Date
2014-07-09
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
699
Registration Number
NCT00189839

A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Liver Transplantation.

Phase 3
Completed
Conditions
Liver Transplantation
Interventions
Drug: tacrolimus
First Posted Date
2005-09-19
Last Posted Date
2014-07-09
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
475
Registration Number
NCT00189826

The Vienna Prograf and Endothelial Progenitor Cell Study

Phase 4
Completed
Conditions
End Stage Renal Disease
Interventions
Drug: Ciclosporin
Drug: Tacrolimus
First Posted Date
2005-09-16
Last Posted Date
2014-02-05
Lead Sponsor
Medical University of Vienna
Target Recruit Count
148
Registration Number
NCT00182559
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients

First Posted Date
2005-09-16
Last Posted Date
2012-10-02
Lead Sponsor
University of Miami
Target Recruit Count
9
Registration Number
NCT00183248
Locations
🇺🇸

University of Miami, Miami, Florida, United States

Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation

Phase 4
Terminated
Conditions
Diabetes Mellitus
Interventions
Drug: Tacrolimus
Drug: Alemtuzumab
First Posted Date
2005-09-15
Last Posted Date
2013-02-07
Lead Sponsor
University of Minnesota
Target Recruit Count
9
Registration Number
NCT00177138
Locations
🇺🇸

University of Minnesota-Fairview, Minneapolis, Minnesota, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy